From the bench to the bed side: PI3K pathway inhibitors in clinical development.
A number of intracellular kinase components of the PI3K/Akt/mTOR pathway have been targeted over the past few years, leading to a new generation of anticancer agents that effectively and specifically disrupt this pathway in tumor cells. Here, progress in the identification and clinical evaluation of compounds designed to modulate the enzymatic activity of PI3K, Akt, mTOR, and Hsp90 is reviewed.
Maira
Saveur-Michel
SM
Oncology Drug Discovery, Novartis Institutes for Biomedical Research, Vitry-sur-Seine Cedex, France.
Finan
Peter
P
Garcia-Echeverria
Carlos
C
D000818:Animals; D001168:Arthritis / Q000188:drug therapy; D055808:Drug Discovery; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D008171:Lung Diseases / Q000188:drug therapy; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
D018841:HSP90 Heat-Shock Proteins; D007527:Isoenzymes; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases